# **QIBA Contrast Enhanced Ultrasound (CEUS) Biomarker Committee (BC) Call**

Friday, May 14, 2021; 11 AM CT Call Summary

### In attendance

Mike Averkiou, PhD (Co-Chair) Todd Erpelding, PhD (Co-Chair) Paul Carson, PhD Sherwin S. Chan, MD, PhD David P. Duncan, PhD, MSE J. Brian Fowlkes, PhD Christian Greis, PhD Gerard (Ged) Harrison, BS Connor Krolak Reinhard Kubale, MD Stefanie Y. Lee, MD, FRCPC Nancy Obuchowski, PhD Bino Varghese, PhD Stephanie Wilson, MD Heng Zhao, MS, PhD **RSNA** Joe Koudelik Julie Lisiecki

Moderator: Dr. Averkiou

## Approval of 4.9.2021 call summary

• The last call summary was approved as presented.

### Update from Q2 US CC meeting

- Dr. Averkiou plans to use the proposed new QIBA Profile Template, which centers around the Checklist, and has a streamlined introduction and executive summary
- Background and supporting scientific rationale would be saved to the appendix
- Dr. Averkiou stressed that Profile authors need to keep the audience in mind
- Per current discussion, the CEUS Profile applies primarily to the research audience, particularly to highly specialized academic centers; it may be used by other community centers/groups in the future

#### **Literature Review**

- Drs. Averkiou and Varghese shared their reviews and insights regarding papers focused on reproducibility
- Drs. Long and McCarville may share additional insights on the next call
- Dr. Averkiou will follow up with Drs. Wilson and Barr regarding sharing their perspectives on clinical applications with reproducibility on upcoming calls (June 11<sup>th</sup> and July 9<sup>th</sup>)
- Dr. Chan volunteered to review 3-4 articles for clinical applicability

#### Discussion

- Dr. Wilson emphasized that the BC's research is important due to variability among scanners in her department
- Clinical focus of the Profile was also discussed, and it was determined that the Profile should more broadly encompass inflammatory bowel disease (IBD) as well as therapy monitoring of liver lesions
- IBD applications provide opportunities for better reproducibility studies and immediate clinical applicability
- Standardization of machine performance would be very beneficial as a Profile goal

#### **Endnote Update**

• Connor Krolak can provide reference details in Endnote and Excel formats; email Connor at: krolakc@uw.edu

#### **Action items**

•

- Share additional literature review on bolus transit reproducibility from Drs. Erpelding, Greis, Long, and McCarville
  - Dr. Averkiou to invite clinician presentations (if available) from Drs. Wilson and Barr
    - $\circ$   $\,$  Dr. Wilson noted that July would be better for her  $\,$
- CEUS BC SMEs are asked to get more involved with the Profile activities
- Participation from BC members with experience with the QIBA Profile-writing process is crucial

### The next scheduled QIBA ultrasound calls will be as follows at 11 am CT, unless otherwise noted:

06/11	CEUS BC
05/19	SWS BC

RSNA Staff attempt to identify and capture all committee members participating on WebEx calls. However, if multiple callers join simultaneously or call in without logging on to the WebEx, identification is not possible Call participants are welcome to contact RSNA staff at <u>QIBA@RSNA.org</u> if their attendance is not reflected on the call summaries.

## Helpful Resources (QIBA wiki):

- Profiles | QIBA Profile template | How to Write a QIBA Profile | Claim Guidance | US Shear Wave Speed Profile
- All Profile Editors are encouraged to join the QIBA Process Committee to learn about QIBA writing tips and processes and network with other Profile Editors to exchange best practices

## **QIBA Process Committee:**

Kevin O'Donnell, MASc (Chair): KOdonnell@MRU.MEDICAL.CANON | Michael Boss, PhD (Chair): mboss@acr.org